Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ADG126 |
Synonyms | |
Therapy Description |
ADG126 is a monoclonal antibody that binds to and inhibits CTLA-4 expressed on T lymphocytes, potentially leading to enhanced antitumor immune response (J Clin Oncol 40, no. 16_suppl (June 01, 2022) e17601-e17601). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ADG126 | ADG-126|ADG 126 | CTLA4 Antibody 31 Immune Checkpoint Inhibitor 149 | ADG126 is a monoclonal antibody that binds to and inhibits CTLA-4 expressed on T lymphocytes, potentially leading to enhanced antitumor immune response (J Clin Oncol 40, no. 16_suppl (June 01, 2022) e17601-e17601). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04645069 | Phase I | ADG126 ADG106 + ADG126 ADG126 + unspecified PD-1 antibody | ADG126, ADG126 in Combination With Toripalimab, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors | Completed | USA | AUS | 1 |
NCT05405595 | Phase I | ADG126 | ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors | Recruiting | USA | 1 |